Efficacy of Empagliflozin in the Treatment of Experimental Myocardial Infarction
Introduction. With the emergence of empagliflozin in the pharmaceutical market, there has been an increase in publications on the primary and secondary pharmacodynamics of the drug, and the list of potential indications for the use of this sodium-glucose co-transporter inhibitor is increasing. Hypot...
Saved in:
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
LLC Center of Pharmaceutical Analytics (LLC «CPHA»)
2023-12-01
|
| Series: | Разработка и регистрация лекарственных средств |
| Subjects: | |
| Online Access: | https://www.pharmjournal.ru/jour/article/view/1640 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849696278698524672 |
|---|---|
| author | D. Yu. Ivkin M. V. Krasnova S. V. Okovity A. A. Karpov A. N. Kulikov E. I. Yeletskaya |
| author_facet | D. Yu. Ivkin M. V. Krasnova S. V. Okovity A. A. Karpov A. N. Kulikov E. I. Yeletskaya |
| author_sort | D. Yu. Ivkin |
| collection | DOAJ |
| description | Introduction. With the emergence of empagliflozin in the pharmaceutical market, there has been an increase in publications on the primary and secondary pharmacodynamics of the drug, and the list of potential indications for the use of this sodium-glucose co-transporter inhibitor is increasing. Hypotheses about pharmacological effects and mechanisms of their implementation are tested both in large-scale clinical studies and in animal experiments.Aim. The purpose of this work was to study the effectiveness of empagliflozin by echocardiographic, histological and molecular biological analyses at the three most significant points of the dynamic transition from acute myocardial infarction to post-infarction chronic heart failure in laboratory male rats.Materials and methods. The experiment was performed on 60 male outbred rats. Myocardial infarction was modeled in narcotic animals by permanent ligation of the left coronary artery. Based on echocardiographic (EchoCG) study data, animals were randomized to two groups: control infarction: untreated pathology group treated with placebo and pathology group treated with empagliflozin 1 mg/kg per os intragastric daily from the first day of the experiment. At 10, 20 and 30 days after the operation, the animals were also subjected to EchoCG testing, and a group of 10 animals from each group were euthanized for histological examination and molecular analysis.Results and discussion. Empagliflozin use in animals after myocardial infarction modeling contributed to a significant increase in myocardial performance on days 10, 20 and 30, reaching a maximum on day 20 (47.58 ± 1.87 %). The drug promotes long-term preservation of the area of damage to the heart muscle with early formation of mature connective tissue, and also increases myocardial resistance to hypoxia by increasing the amount of HIF-1.Conclusion. Based on the studies carried out, it can be concluded that it is possible to use the sodium-glucose cotransporter type 2 empagliflozin in the formation of post-infarction chronic heart failure in the conditions of normoglycemia. |
| format | Article |
| id | doaj-art-39dd9de997ec43cdbc9285d6ecf2d183 |
| institution | DOAJ |
| issn | 2305-2066 2658-5049 |
| language | Russian |
| publishDate | 2023-12-01 |
| publisher | LLC Center of Pharmaceutical Analytics (LLC «CPHA») |
| record_format | Article |
| series | Разработка и регистрация лекарственных средств |
| spelling | doaj-art-39dd9de997ec43cdbc9285d6ecf2d1832025-08-20T03:19:31ZrusLLC Center of Pharmaceutical Analytics (LLC «CPHA»)Разработка и регистрация лекарственных средств2305-20662658-50492023-12-0112413614510.33380/2305-2066-2023-12-4-15881159Efficacy of Empagliflozin in the Treatment of Experimental Myocardial InfarctionD. Yu. Ivkin0M. V. Krasnova1S. V. Okovity2A. A. Karpov3A. N. Kulikov4E. I. Yeletskaya5Saint-Petersburg State Chemical and Pharmaceutical UniversitySaint-Petersburg State Chemical and Pharmaceutical UniversitySaint-Petersburg State Chemical and Pharmaceutical UniversityAlmazov National Medical Research CentreFSBEI HE I.P. Pavlov SPbSMU MOH RussiaSaint-Petersburg State Chemical and Pharmaceutical UniversityIntroduction. With the emergence of empagliflozin in the pharmaceutical market, there has been an increase in publications on the primary and secondary pharmacodynamics of the drug, and the list of potential indications for the use of this sodium-glucose co-transporter inhibitor is increasing. Hypotheses about pharmacological effects and mechanisms of their implementation are tested both in large-scale clinical studies and in animal experiments.Aim. The purpose of this work was to study the effectiveness of empagliflozin by echocardiographic, histological and molecular biological analyses at the three most significant points of the dynamic transition from acute myocardial infarction to post-infarction chronic heart failure in laboratory male rats.Materials and methods. The experiment was performed on 60 male outbred rats. Myocardial infarction was modeled in narcotic animals by permanent ligation of the left coronary artery. Based on echocardiographic (EchoCG) study data, animals were randomized to two groups: control infarction: untreated pathology group treated with placebo and pathology group treated with empagliflozin 1 mg/kg per os intragastric daily from the first day of the experiment. At 10, 20 and 30 days after the operation, the animals were also subjected to EchoCG testing, and a group of 10 animals from each group were euthanized for histological examination and molecular analysis.Results and discussion. Empagliflozin use in animals after myocardial infarction modeling contributed to a significant increase in myocardial performance on days 10, 20 and 30, reaching a maximum on day 20 (47.58 ± 1.87 %). The drug promotes long-term preservation of the area of damage to the heart muscle with early formation of mature connective tissue, and also increases myocardial resistance to hypoxia by increasing the amount of HIF-1.Conclusion. Based on the studies carried out, it can be concluded that it is possible to use the sodium-glucose cotransporter type 2 empagliflozin in the formation of post-infarction chronic heart failure in the conditions of normoglycemia.https://www.pharmjournal.ru/jour/article/view/1640myocardial infarctionsglt2 inhibitorsechocardiogrammolecular biological analysishistology |
| spellingShingle | D. Yu. Ivkin M. V. Krasnova S. V. Okovity A. A. Karpov A. N. Kulikov E. I. Yeletskaya Efficacy of Empagliflozin in the Treatment of Experimental Myocardial Infarction Разработка и регистрация лекарственных средств myocardial infarction sglt2 inhibitors echocardiogram molecular biological analysis histology |
| title | Efficacy of Empagliflozin in the Treatment of Experimental Myocardial Infarction |
| title_full | Efficacy of Empagliflozin in the Treatment of Experimental Myocardial Infarction |
| title_fullStr | Efficacy of Empagliflozin in the Treatment of Experimental Myocardial Infarction |
| title_full_unstemmed | Efficacy of Empagliflozin in the Treatment of Experimental Myocardial Infarction |
| title_short | Efficacy of Empagliflozin in the Treatment of Experimental Myocardial Infarction |
| title_sort | efficacy of empagliflozin in the treatment of experimental myocardial infarction |
| topic | myocardial infarction sglt2 inhibitors echocardiogram molecular biological analysis histology |
| url | https://www.pharmjournal.ru/jour/article/view/1640 |
| work_keys_str_mv | AT dyuivkin efficacyofempagliflozininthetreatmentofexperimentalmyocardialinfarction AT mvkrasnova efficacyofempagliflozininthetreatmentofexperimentalmyocardialinfarction AT svokovity efficacyofempagliflozininthetreatmentofexperimentalmyocardialinfarction AT aakarpov efficacyofempagliflozininthetreatmentofexperimentalmyocardialinfarction AT ankulikov efficacyofempagliflozininthetreatmentofexperimentalmyocardialinfarction AT eiyeletskaya efficacyofempagliflozininthetreatmentofexperimentalmyocardialinfarction |